Kinaxo’s phosphoproteomics platform, PhosphoScout enables the identification of regulated protein phosphorylation sites in response to therapeutic antibody or kinase inhibitor treatment. Using the quantitative mass spectrometry, up to 15,000 phosphorylation sites can be monitored in a single experiment, thereby facilitating analysis of the phosphoproteome in patient samples, animal models and cell culture on a global scale.
Unlike immunoassays, PhosphoScout does not require antibodies for detection, thus enabling unbiased, comprehensive phosphoproteome analyses across entire signaling pathways. This positions PhosphoScout as an upcoming technology for drug mode of action analysis and the stratification of cancer patients receiving targeted therapies, said the company.